Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Phase II evaluation of chlorozotocin in refractory multiple myeloma.

Publication ,  Journal Article
Forman, WB; Cohen, HJ; Bartolucci, AA; Manning, G
Published in: Cancer Treat Rep
November 1984

Duke Scholars

Published In

Cancer Treat Rep

ISSN

0361-5960

Publication Date

November 1984

Volume

68

Issue

11

Start / End Page

1409 / 1410

Location

United States

Related Subject Headings

  • Streptozocin
  • Multiple Myeloma
  • Humans
  • Drug Evaluation
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Forman, W. B., Cohen, H. J., Bartolucci, A. A., & Manning, G. (1984). Phase II evaluation of chlorozotocin in refractory multiple myeloma. Cancer Treat Rep, 68(11), 1409–1410.
Forman, W. B., H. J. Cohen, A. A. Bartolucci, and G. Manning. “Phase II evaluation of chlorozotocin in refractory multiple myeloma.Cancer Treat Rep 68, no. 11 (November 1984): 1409–10.
Forman WB, Cohen HJ, Bartolucci AA, Manning G. Phase II evaluation of chlorozotocin in refractory multiple myeloma. Cancer Treat Rep. 1984 Nov;68(11):1409–10.
Forman, W. B., et al. “Phase II evaluation of chlorozotocin in refractory multiple myeloma.Cancer Treat Rep, vol. 68, no. 11, Nov. 1984, pp. 1409–10.
Forman WB, Cohen HJ, Bartolucci AA, Manning G. Phase II evaluation of chlorozotocin in refractory multiple myeloma. Cancer Treat Rep. 1984 Nov;68(11):1409–1410.

Published In

Cancer Treat Rep

ISSN

0361-5960

Publication Date

November 1984

Volume

68

Issue

11

Start / End Page

1409 / 1410

Location

United States

Related Subject Headings

  • Streptozocin
  • Multiple Myeloma
  • Humans
  • Drug Evaluation
  • Antineoplastic Agents